2.00Open2.00Pre Close0 Volume5 Open Interest4.00Strike Price0.00Turnover2173.08%IV-61.22%PremiumDec 20, 2024Expiry Date11.47Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9719Delta0.0044Gamma1.32Leverage Ratio-0.6706Theta0.0001Rho1.28Eff Leverage0.0004Vega
uniQure NV Stock Discussion
Benzinga· 3 mins ago
-As part of uniQure's Regenerative Medicine Advanced Therapy (RMAT) Type B meeting held in late November, the FDA agreed that data from the ongoing Phase I/II studies, compared to a natural history external control, may serve as the primary basis for a BLA submission under the Accelerated Approval pathway, avoiding the need for an additional pre-submiss...
uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease
uniQure has reached an agreement with the FDA on key elements for an Accelerated Approval pathway for AMT-130, their Huntington's disease treatment. The FDA agreed that data from ongoing Phase I/II studies compared to natural history external control can serve as the primary basis for a Biologics License Application (BLA), eliminating the need for ad...
4 MINUTES AGO, 7:05 AM EST
VIA GLOBENEWSWIRE
I went with the wrong Curi! lol, both are good LT though
$uniQure NV (QURE.US)$
No comment yet